Deciding which selective serotonin reuptake inhibitor to prescribe

BMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7020.1641a (Published 16 December 1995) Cite this as: BMJ 1995;311:1641
  1. Anthony J Cleare, Lecturer in liaison psychiatry Department of Psychological Medicine, Institute of Psychiatry
  1. London SE5 8AZ

    EDITOR,--Recent articles have debated the relative costs of selective serotonin reuptake inhibitors for depression in relation to their tolerability and efficacy.1 2 I M Anderson and B M Tomenson raise the point that cost-benefit analyses should include real life prescribing situations rather than the atypical situations found in short clinical trials.1

    Intense media publicity and debate have been given to …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription